Elizabeth Cairns
Senior Writer
A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.
Latest From Elizabeth Cairns
Roche’s New Obesity Play Shows Early Promise
CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.
Development Versus Dealmaking: How To Obtain A Blockbuster
Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.
Merck KGaA’s Dealmaking Slows
And the deals it has signed recently will not begin to pay off for some years to come.
Novo Takes On Roche In Hemophilia
Mim8 looks good in hemophilia A but Hemlibra’s lead is all but unassailable.
Blockbusters By Indication: More Begets More
A Scrip analysis of the industry’s top-selling drugs examines the power of indication expansion to drive revenue growth.
Sanofi’s $500m COVID-19 Deal Comes Four Years Too Late
But it rescues embattled Novavax.